Sustainable Health Services for Hepatocellular Carcinoma Survivors in Thailand: Financial and Social Experiences from a Cross-Sectional Study

Main Article Content

Passakorn Wanchaijiraboon
Naiyarat Prasongsook
Krit Pongpirul
Chitsanucha Chumsri
Piyawat Kantagowit
Phanupong Phutrakool
Pisit Tangkijvanich
Wattana Sukeepaisarnjareon

Abstract

BACKGROUND: Despite advances in medical treatments that have extended survival among patients with hepatocellular carcinoma (HCC) in many developed countries, significant challenges continue to persist in Thailand, even with the Universal Coverage Scheme.


OBJECTIVES This study aimed to understand the socioeconomic experiences of HCC survivors to inform improvements in national health insurance policies and clinical care.


METHODS: A multicenter cross-sectional survey was conducted at major Thai liver cancer centers. HCC patients attending outpatient clinics were invited to participate and provide information on demographic characteristics, social experiences, financial barriers, perspectives on existing support policies, and the perceived benefits of increased public awareness. Ethical approvals were obtained from all participating centers.


RESULTS: Among the 92 respondents (mean age 62.1±11.5 years; 78.3% male), 65.2% reported that medical expenses influenced their treatment decisions, and 71.7% experienced family-related financial difficulties. Socially, 97.8% felt understood by friends and family, while 47.8% reported that their illness affected personal relationships. Most participants indicated a need for mental support (98.9%), financial assistance (91.3%), and improved public awareness to enhance their quality of life (98.9%).


CONCLUSIONS: Thai HCC survivors face significant financial barriers to access advanced treatments but receive considerable community support. These findings highlight the need to refine Thailand’s health insurance framework to better address the financial and social needs of HCC patients.

Article Details

Section
Original Article

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.

Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular carcinoma: an overview of the changing landscape of treatment options. J Hepatocell Carcinoma 2021;8:387-401.

Kohn CG, Singh P, Korytowsky B, Caranfa JT, Miller JD, Sill BE, et al. Humanistic and economic burden of hepatocellular carcinoma: systematic literature review. Am J Manag Care 2019;25(2 Spec No.):SP61-SP73.

Guo A, Pomenti S, Wattacheril J. Health disparities in screening, diagnosis, and treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2021;17:353-8.

Sritunyarat Y, Phathong C, Tangkijvanich P, Treeprasertsuk S, Rerknimitr R, Chaiteerakij R. Barriers to hepatocellular carcinoma (HCC) surveillance in Thailand. Gastroenterology. 2017;152:S1184-5.

Chonprasertsuk S, Vilaichone RK. Epidemiology and treatment of hepatocellular carcinoma in Thailand. Jpn J Clin Oncol 2017;47:294-7.

Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58.

Hansen L, Dieckmann NF, Kolbeck KJ, Naugler WE, Chang MF. Symptom distress in patients with hepatocellular carcinoma toward the end of life. Oncol Nurs Forum 2017;44:665-73.

Klein J, Dawson LA, Jiang H, Kim J, Dinniwell R, Brierley J, et al. Prospective longitudinal assessment of quality of life for liver cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2015;93:16-25.

Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes 2014;108:397-404.

Bou-Samra P, Scott P, Cheng H, Kallem C, Pathak R, Geller DA, et al. Social support is associated with survival in patients diagnosed with gastrointestinal cancer. J Gastrointest Cancer 2022;53:854-61.

Reblin M, Uchino BN. Social and emotional support and its implication for health. Curr Opin Psychiatry 2008;21:201-5.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.

Gandhi S, Khubchandani S, Iyer R. Quality of life and hepatocellular carcinoma. J Gastrointest Oncol 2014;5:296-317.